

Anti-IL-6 receptor (Tocilizumab), Human IgG1 Antibody

CATALOG NO:	A1447-200
AMOUNT:	200 µg
ALTERNATE NAMES:	Actemra, Tocilizumab/Atlizumab, tocilizumab, rotocilizumab, 375823-41-9, atlizumab, tocilizumab, Rotocilizumab, IL6R, interleukin 6 receptor
ISOTYPE / FORMAT:	Human IgG1, kappa
CLONALITY:	Monoclonal
CLONE:	rhPM-1 (Tocilizumab)
SPECIES REACTIVITY:	Human
IMMUNOGEN:	This antibody was prepared by CDR grafting of mouse AUK 12-20 antibody onto a human framework regions.
FORM:	Liquid
SPECIFICITY:	Tocilizumab binds specifically to both the membrane bound and soluble forms of human IL-6R. The IL6 receptor is a protein complex consisting of an IL-6 receptor subunit (IL6R) and interleukin 6 signal transducer Glycoprotein 130. Interleukin 6 (IL6) is a potent pleiotropic cytokine that regulates cell growth and differentiation and plays an important role in immune response.
PURIFICATION:	Affinity purified using Protein A
FORMULATION:	Supplied in PBS only
STORAGE CONDITIONS:	Store at 4°C for upto 3 months. For long term storage, aliquot and freeze at -20°C. Avoid repeated freeze/thaw cycles.
DESCRIPTION:	Recombinant monoclonal antibody to IL-6 receptor. Manufactured using Recombinant Platform with variable regions (i.e. specificity) from the therapeutic antibody rhPM-1 (Tocilizumab).
APPLICATION:	Tocilizumab can be used in ELISA assays and is able to inhibit the growth of IL-6-dependent tumor cell lines (to the same extent as the original AUK12-20 mouse antibody) - inhibits sIL-6R and mIL-6R-mediated signaling.
REFERENCE:	Sato <i>et al.</i> Humanization of a mouse anti-human interleukin-6 receptor antibody comparing two methods for selecting human framework regions. Mol Immunol. 1994 Apr;31(5):371-81.

RELATED PRODUCTS:

- Anti-VEGF (Bevacizumab), humanized Antibody (**Cat. No. A1045**)
- Anti-HER2 (Trastuzumab), humanized Antibody (**Cat. No. A1046**)
- Anti-EGFR (Cetuximab), Chimeric Antibody (**Cat. No. A1047**)
- Anti-TNF-α (Adalimumab), humanized Antibody (**Cat. No. A1048**)
- Anti-CD20 (Rituximab), Chimeric Antibody (**Cat. No. A1049**)
- Anti-EGFR (Panitumumab), humanized antibody (**Cat. No. A1050**)
- Anti-OX40L (Oxelumab), Human IgG1 Antibody (**Cat. No. A1088**)
- Anti-CD11a (Efalizumab), Human IgG1 Antibody (**Cat. No. A1089**)
- Anti-EGFR (Matuzumab), Human IgG1 Antibody (**Cat. No. A1090**)
- Anti-CD4 (Clenoliximab), Human IgG4 Antibody (**Cat. No. A1091**)
- Anti-alpha 5 beta1 Integrin (Volociximab), Human IgG4 Antibody (**Cat. No. A1092**)
- Anti-TNF alpha (Humicade), Human IgG4 Antibody (**Cat. No. A1093-200**)
- Anti-CD40L (Ruplizumab), Human IgG1 Antibody (**Cat. No. A1094-200**)
- Anti-Human Ephrin Type A receptor 2 (1C1), Human IgG1 Antibody (**Cat. No. A1095**)
- Anti-Carcinoembryonic antigen (Arcitumomab), Human IgG1 Antibody (**Cat. No. A1096**)
- Anti-TNF alpha (Infliximab), Human IgG1 Antibody (**Cat. No. A1097**)
- Anti-IL-2R alpha (CD25) (Basiliximab), Human IgG1 Antibody (**Cat. No. A1098**)

FOR RESEARCH USE ONLY! Not to be used on humans.